论文部分内容阅读
目的 评价非小细胞肺癌裸鼠体内肿瘤药物筛选结果及临床应用疗效。方法 新鲜非小细胞肺癌组织块植入裸鼠肾包膜下 ,选用常用抗非小细胞肺癌药物进行肿瘤药敏试验。临床实验组依据肿瘤药敏结果进行肺癌根治术后辅助化学治疗 ;临床对照组选取同期非小细胞肺癌根治术后接受CAP方案辅助化学治疗。结果 人体癌细胞植入裸鼠体内后能很好地保持肿瘤细胞形态 ,移植瘤细胞可见率为 87 8%。临床实验组 3a生存率为 60 0 % ,临床对照组 3a生存率为 5 0 0 % ,差异无显著性 (P >0 0 5 ) ,两组Ⅲ期 3a生存率分别为 5 2 6%和 3 3 3 % ,差异有显著性 (P <0 0 5 )。结论 裸鼠肾包膜下筛选抗肿瘤药物进行术后辅助化疗有非常显著临床效果 ,3a生存率有一定提高 ,避免肿瘤化学治疗上的盲目性。
Objective To evaluate the drug screening results and clinical efficacy of non-small cell lung cancer in nude mice. Methods Fresh non-small cell lung cancer (NSCLC) was implanted into the subrenal capsule of nude mice, and commonly used non-small cell lung cancer (NSCLC) drugs were used for tumor susceptibility testing. The clinical trial group was based on the results of tumor susceptibility for adjuvant chemotherapy after lung cancer resection; the clinical control group was selected for concurrent non-small cell lung cancer after radical resection for CAP regimen adjuvant chemotherapy. Results Human cancer cells could maintain the morphology of tumor cells after implanted in nude mice. The observed rate of transplanted tumor cells was 87.8%. The 3a survival rate in the clinical trial group was 60.0%, and the 3a survival rate in the clinical control group was 500.0%. There was no significant difference (P > 0 05). The 3a 3a survival rates in the two groups were 5 2 6% and 3, respectively. 3 3%, the difference was significant (P <0 05). Conclusion The screening of anti-tumor drugs underneath the kidney of nude mice for postoperative adjuvant chemotherapy has a very significant clinical effect, and the 3a survival rate has been improved to avoid blindness in tumor chemotherapy.